Apollon Wealth Management LLC Lowers Position in DexCom, Inc. (NASDAQ:DXCM)

Apollon Wealth Management LLC lowered its holdings in DexCom, Inc. (NASDAQ:DXCM) by 3.1% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 21,974 shares of the medical device company’s stock after selling 696 shares during the quarter. Apollon Wealth Management LLC’s holdings in DexCom were worth $2,727,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the business. Sands Capital Management LLC increased its holdings in shares of DexCom by 4.3% in the 3rd quarter. Sands Capital Management LLC now owns 13,660,670 shares of the medical device company’s stock valued at $1,274,541,000 after acquiring an additional 557,543 shares during the period. Blair William & Co. IL raised its stake in shares of DexCom by 1.7% during the 3rd quarter. Blair William & Co. IL now owns 4,507,153 shares of the medical device company’s stock worth $420,517,000 after acquiring an additional 73,654 shares in the last quarter. Northern Trust Corp lifted its position in DexCom by 2.4% during the third quarter. Northern Trust Corp now owns 3,896,515 shares of the medical device company’s stock valued at $363,545,000 after acquiring an additional 91,249 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in DexCom by 1.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 2,160,961 shares of the medical device company’s stock valued at $201,618,000 after acquiring an additional 28,621 shares in the last quarter. Finally, Winslow Capital Management LLC purchased a new position in DexCom in the third quarter worth $173,120,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insider Buying and Selling at DexCom

In related news, EVP Sadie Stern sold 20,321 shares of the company’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $133.61, for a total transaction of $2,715,088.81. Following the completion of the transaction, the executive vice president now owns 80,441 shares in the company, valued at approximately $10,747,722.01. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, CFO Jereme M. Sylvain sold 3,363 shares of the company’s stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $116.73, for a total transaction of $392,562.99. Following the completion of the sale, the chief financial officer now owns 71,142 shares of the company’s stock, valued at approximately $8,304,405.66. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Sadie Stern sold 20,321 shares of the stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $133.61, for a total value of $2,715,088.81. Following the transaction, the executive vice president now owns 80,441 shares of the company’s stock, valued at $10,747,722.01. The disclosure for this sale can be found here. Insiders have sold a total of 190,004 shares of company stock valued at $25,610,270 over the last ninety days. Corporate insiders own 0.41% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently commented on DXCM shares. Raymond James increased their price objective on DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a report on Friday, April 26th. Canaccord Genuity Group raised their price target on DexCom from $144.00 to $145.00 and gave the stock a “buy” rating in a report on Friday, April 26th. StockNews.com upgraded shares of DexCom from a “hold” rating to a “buy” rating in a report on Wednesday, May 1st. Citigroup lifted their target price on shares of DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Finally, UBS Group upped their price target on shares of DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research note on Wednesday, April 10th. Two investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, DexCom has an average rating of “Moderate Buy” and a consensus price target of $141.67.

DexCom Stock Performance

DXCM stock traded up $0.45 during midday trading on Tuesday, hitting $130.10. 1,425,158 shares of the stock traded hands, compared to its average volume of 2,999,962. The stock’s fifty day simple moving average is $132.38 and its 200-day simple moving average is $120.80. The firm has a market cap of $51.74 billion, a P/E ratio of 83.90, a PEG ratio of 2.19 and a beta of 1.23. DexCom, Inc. has a 1-year low of $74.75 and a 1-year high of $142.00. The company has a debt-to-equity ratio of 1.08, a current ratio of 2.90 and a quick ratio of 2.53.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, April 25th. The medical device company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. The firm had revenue of $921.00 million for the quarter, compared to analysts’ expectations of $911.20 million. DexCom had a return on equity of 31.01% and a net margin of 16.82%. On average, analysts expect that DexCom, Inc. will post 1.78 earnings per share for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.